Sign in or create an account to add this stock to your watchlist.
About Aegerion Pharmaceuticals (NASDAQ:AEGR)
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:AEGR
CUSIP00767E10
Phone+1-617-5007867
Debt
Debt-to-Equity Ratio-19.22
Current Ratio1.02
Quick Ratio0.67
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-75.07%
Return on EquityN/A
Return on Assets-29.21%
Miscellaneous
Employees318
Outstanding Shares29,540,000
Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions
What is Aegerion Pharmaceuticals' stock symbol?
Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."
How were Aegerion Pharmaceuticals' earnings last quarter?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company earned $35.70 million during the quarter, compared to analyst estimates of $43 million. The firm's revenue was down 39.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.
Has Aegerion Pharmaceuticals been receiving favorable news coverage?
Media stories about AEGR stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a news impact score of 0.23 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Aegerion Pharmaceuticals?
Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aegerion Pharmaceuticals' stock price today?
One share of AEGR stock can currently be purchased for approximately $1.97.
How big of a company is Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe.
How can I contact Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.
MarketBeat Community Rating for Aegerion Pharmaceuticals (AEGR)
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aegerion Pharmaceuticals (NASDAQ:AEGR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | Hold |
| Consensus Rating Score: | N/A | N/A | N/A | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $1.50 |
| Price Target Upside: | N/A | N/A | N/A | 23.86% downside |
Aegerion Pharmaceuticals (NASDAQ:AEGR) Consensus Price Target History
Aegerion Pharmaceuticals (NASDAQ:AEGR) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/30/2016 | Cowen | Reiterated Rating | Hold | $1.50 | N/A |  |
| 11/11/2016 | JPMorgan Chase & Co. | Initiated Coverage | Hold | | N/A | |
(Data available from 5/23/2016 forward)
Aegerion Pharmaceuticals (NASDAQ:AEGR) Earnings History and Estimates Chart
Aegerion Pharmaceuticals (NASDAQ AEGR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/3/2016 | Q3 2016 | ($0.67) | ($0.46) | $27.00 million | $35.39 million | View | N/A | |
| 8/9/2016 | Q2 2016 | ($0.25) | ($0.87) | | $44.53 million | View | N/A | |
| 5/16/2016 | Q1 | ($0.58) | ($1.72) | $43.00 million | $35.70 million | View | Listen | |
| 2/25/2016 | Q4 | ($0.89) | ($0.69) | $47.74 million | $49.00 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.42) | ($0.34) | $59.72 million | $67.30 million | View | N/A | |
| 8/5/2015 | Q2 | ($0.27) | ($0.01) | $58.98 million | $64.20 million | View | N/A | |
| 5/4/2015 | Q1 2015 | ($0.27) | ($0.19) | $50.42 million | $59.38 million | View | N/A | |
| 2/26/2015 | Q4 2014 | $0.05 | ($0.12) | $49.20 million | $51.71 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.18) | ($0.12) | $48.60 million | $43.70 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.41) | ($0.33) | $35.40 million | $36.00 million | View | Listen | |
| 5/6/2014 | Q1 | ($0.35) | ($0.54) | $33.58 million | $27.00 million | View | Listen | |
| 2/26/2014 | Q413 | ($0.30) | ($0.14) | $24.51 million | $24.50 million | View | Listen | |
| 10/29/2013 | Q313 | ($0.50) | ($0.43) | $13.07 million | $16.30 million | View | N/A | |
| 7/30/2013 | Q2 2013 | ($0.62) | ($0.66) | $4.27 million | $6.50 million | View | N/A | |
| 4/30/2013 | Q1 2013 | ($0.72) | ($0.64) | $1.07 million | $1.23 million | View | N/A | |
| 3/6/2013 | Q4 2012 | ($0.62) | ($0.86) | | | View | N/A | |
| 11/7/2012 | Q312 | ($0.56) | ($0.59) | | | View | N/A | |
| 8/8/2012 | Q2 2012 | ($0.54) | ($0.60) | | | View | N/A | |
| 5/1/2012 | Q1 2012 | ($0.59) | ($0.51) | | | View | N/A | |
| 3/6/2012 | Q4 2011 | ($0.54) | ($0.61) | | | View | N/A | |
| 10/27/2011 | Q3 2011 | ($0.45) | ($0.48) | | | View | N/A | |
| 7/27/2011 | Q2 2011 | ($0.40) | ($0.49) | | | View | N/A | |
| 4/28/2011 | Q1 2011 | ($0.42) | ($0.39) | | | View | N/A | |
| 3/2/2011 | Q4 2010 | ($0.34) | ($0.92) | | | View | N/A | |
| 11/30/2010 | Q3 2010 | | ($3.61) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Aegerion Pharmaceuticals (NASDAQ:AEGR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aegerion Pharmaceuticals (NASDAQ AEGR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Aegerion Pharmaceuticals (NASDAQ AEGR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/13/2016 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 75,000 | $1.75 | $131,250.00 | | |
| 9/12/2016 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 276,000 | $1.66 | $458,160.00 | | |
| 8/19/2014 | Mark J Fitzpatrick | CFO | Buy | 1,150 | $30.64 | $35,236.00 | | |
| 7/31/2014 | Marc D Beer | CEO | Buy | 10,000 | $33.65 | $336,500.00 | | |
| 6/3/2014 | Marc D Beer | CEO | Buy | 10,000 | $30.12 | $301,200.00 | | |
| 5/27/2014 | Marc D Beer | CEO | Buy | 10,000 | $31.59 | $315,900.00 | | |
| 5/20/2014 | Marc Beer | CEO | Buy | 10,000 | $30.53 | $305,300.00 | 43,000 | |
| 5/8/2014 | Anne Vanlent | Director | Buy | 4,000 | $33.78 | $135,120.00 | 4,000 | |
| 5/8/2014 | Marc Beer | CEO | Buy | 30,000 | $35.31 | $1,059,300.00 | 33,000 | |
| 4/30/2014 | Craig Fraser | Insider | Sell | 2,250 | $43.55 | $97,987.50 | | |
| 3/31/2014 | Craig Fraser | Insider | Sell | 2,250 | $46.20 | $103,950.00 | | |
| 3/14/2014 | Mark Sumeray | Insider | Sell | 2,000 | $51.34 | $102,680.00 | | |
| 2/11/2014 | Craig Fraser | Insider | Sell | 2,250 | $67.00 | $150,750.00 | | |
| 12/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $66.34 | $132,680.00 | | |
| 10/30/2013 | Marc D Beer | CEO | Sell | 40,000 | $87.79 | $3,511,600.00 | | |
| 10/29/2013 | Sandford D Smith | Director | Sell | 2,502 | $95.00 | $237,690.00 | | |
| 10/15/2013 | Mark Sumeray | Insider | Sell | 2,000 | $80.33 | $160,660.00 | | |
| 10/7/2013 | Mark Sumeray | Insider | Sell | 3,500 | $93.17 | $326,095.00 | | |
| 9/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $89.77 | $179,540.00 | | |
| 9/5/2013 | Perceptive Advisors Llc | Major Shareholder | Sell | 750,000 | $89.20 | $66,900,000.00 | | |
| 8/21/2013 | David Scheer | Director | Sell | 20,000 | $84.58 | $1,691,600.00 | 10,000 | |
| 8/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $88.71 | $177,420.00 | | |
| 8/15/2013 | Marc Beer | CEO | Sell | 60,000 | $88.54 | $5,312,400.00 | 199,061 | |
| 8/14/2013 | Mark Fitzpatrick | CFO | Sell | 7,500 | $93.44 | $700,800.00 | 500 | |
| 8/12/2013 | Sandford Smith | Director | Sell | 10,000 | $92.32 | $923,200.00 | | |
| 7/15/2013 | Mark Sumeray | Insider | Sell | 2,000 | $78.77 | $157,540.00 | | |
| 6/17/2013 | Mark Sumeray | Insider | Sell | 6,000 | $65.27 | $391,620.00 | | |
| 5/15/2013 | Mark Sumeray | Insider | Sell | 6,000 | $47.32 | $283,920.00 | | |
| 2/1/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $27.79 | $1,389,500.00 | | |
| 1/18/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $27.62 | $1,381,000.00 | | |
| 1/17/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $26.73 | $1,336,500.00 | | |
| 1/11/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 475,000 | $27.07 | $12,858,250.00 | | |
| 12/4/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 20,000 | $21.27 | $425,400.00 | | |
| 11/29/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 30,000 | $22.71 | $681,300.00 | | |
| 11/28/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 150,000 | $21.25 | $3,187,500.00 | | |
(Data available from 1/1/2013 forward)
Aegerion Pharmaceuticals (NASDAQ AEGR) News Headlines
| Source: |
|
Aegerion Pharmaceuticals (NASDAQ:AEGR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aegerion Pharmaceuticals (NASDAQ:AEGR) Income Statement, Balance Sheet and Cash Flow Statement
Aegerion Pharmaceuticals (NASDAQ AEGR) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
